Scientists compare two formulations of a potential asthma treatment
NCT ID NCT07712393
First seen Jul 17, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This study tests two different versions of an experimental drug called GSK5784283 in healthy adults. The goal is to see how each formulation moves through the body and whether they work similarly. Researchers will also check for safety and side effects. The results will help decide which formulation to use in future studies for asthma.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- an experimental drug called GSK5784283
- What this could lead to
- If successful, this study could help determine the best formulation of GSK5784283 for future asthma trials.
- What could go wrong
- This is an early Phase 1 study in only 24 healthy volunteers, so results may not predict effects in people with asthma. The drug may not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECG. * Body weight greater than or equal (\>=) 50 kilogram (kg) (110 pounds \[lbs\]) and body mass index within the range 19 to 30 kilogram per meter square (kg/m\^2) (inclusive). * A female participant is eligible to participate if she is a participant of non-childbearing potential (PONCBP) as specified in the protocol. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. Exclusion Criteria: * Hypersensitivity- Participants with allergy/intolerance to any biologic therapy or any of the known excipients used in products administered subcutaneously * History or presence of any clinically significant medical condition capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data. * Any clinically relevant abnormal findings in physical examination, hematology, clinical chemistry, urinalysis, vital signs during screening period which in the opinion of the investigator, may put the subject at risk because of his/her participation in the study, or may influence the results of the study, or the subject's ability to participate in the study. * Live vaccine(s) within 1 month prior to screening or plans to receive such vaccines during the clinical study. * Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to study intervention administration. * Current smokers (tobacco and/or marijuana) or former smokers with a smoking history \>10 pack-years and participants using vaping products, including electronic cigarettes. * Regular alcohol consumption that exceeds the limits specified in the protocol * Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the clinical study. * The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF), machine-read or manually over-read \>450 millisecond (msec).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Asthma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
GSK Investigational Site
RECRUITINGAustin, Texas, 78744, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single triple inhaler tame asthma in the real world?
- Can a Three-Drug inhaler outperform the standard Two-Drug treatment for asthma?
- Can a new inhaler match Symbicort's performance?
- Fine-Mist inhalers aim to reach deep lungs in COPD
- Can a hormone supplement tame asthma?
- A wearable stethoscope may let kids with asthma monitor their lungs at home